Antibiotic resistance in Staphylococcus aureus: Concerns, causes and cures

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 1, 2003, Pages 45-55

  Chopra, Ian ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Analog expansion; Antibiotic resistance; Genomics; MRSA; Multiple target blockade new drug discovery; Old pharmacophores; Peptide deformylase inhibitors; RNA polymerase inhibitors

Indexed keywords

1 (6 AMINO 3,5 DIFLUORO 2 PYRIDYL) 8 CHLORO 6 FLUORO 1,4 DIHYDRO 7 (3 HYDROXY 1 AZETIDINYL) 4 OXO 3 QUINOLINECARBOXYLIC ACID; 7 [[(2 AMINO 5 CHLORO 4 THIAZOLYL)(HYDROXYIMINO)ACETYL]AMINO] 3 [[3 [[(2 AMINOETHYL)THIO]METHYL] 4 PYRIDINYL]THIO] 8 OXO 5 THIA 1 AZABICYCLO[4.2.0]OCT 2 ENE 2 CARBOXYLIC ACID; 7BETA [2 (5 AMINO 1,2,4 THIADIAZOL 3 YL) 2 ETHOXYIMINOACETAMIDO] 3 [(1 METHYLAMINOPROPYL 1H IMIDAZO[4,5 B]PYRIDINIUM 4 YL)METHYL] 3 CEPHEM 4 CARBOXYLIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTOBIPROLE MEDOCARIL; CEPHALOSPORIN DERIVATIVE; CLOFAZIMINE; DALBAVANCIN; DRF 8417; FUSIDIC ACID; GENTAMICIN; LINEZOLID; MACROLIDE; METICILLIN; ORITAVANCIN; OXAZOLIDINONE DERIVATIVE; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANBEZOLID; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAPENTINE; SITAFLOXACIN; STREPTOGRAMIN DERIVATIVE; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BINDING SITE; CLINICAL TRIAL; DRUG BINDING; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; LEPROSY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; REVIEW; SKIN DISCOLORATION; STAPHYLOCOCCUS INFECTION;

EID: 1542302583     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.1.1.45     Document Type: Review

References (46)

1. Chopra I, Hesse L, O'Neill AJ. Exploiting current understanding of antibiotic action for discovery of new drugs. J. Appl. Microbiol. Symp. Suppl. 92, 4S-15S (2002).
2. Cohen ML. Changing patterns of infectious disease. Nature 406, 762-767 (2000).
3. Coates A, Hu Y, Bax R et al. The future challenges facing the development of new antimicrobial drugs. Nature Rev. Drug Disc. 1, 895-910 (2002).
4. Plowman R, Graves N, Griffin MA et al. The rate and cost of hospital-acquired infections occurring in patients admitted to selected specialities of a district general hospital in England and the national burden imposed. J. Hosp. Infect. 47, 198-209 (2001).
5. Pfaller MA, Jones RN, Doern GV et al. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob. Agents Chemother. 42, 1762-1770 (1998).
6. Public Health Laboratory Service. Antimicrobial Resistance in 2000: England and Wales. In: London: Public Health Laboratory Service (2002).
7. Avison MB, Bennett PM, Howe RA et al. Preliminary analysis of the genetic basis for vancomycin resistance in Staphylococcus aureus strain Mu50. J. Antimicrob. Chemother. 49, 255-260 (2002).
8. Centers for Disease Control. Staphylococcus aureus resistant to vancomycin - United States 2002. Morbid Mortal. Weekly Rep. 51, 565-567 (2002).
9. Centers for Disease Control. Vancomycin-resistant Staphylococcus aureus - Pennsylvania 2002. Morbid. Mortal. Weekly Rep. 51, 902 (2002).
10. Gonzalez-Zorn B, Courvalin P. vanA-mediated high level glycopeptide resistance in MRSA. Lancet Infect. Dis. 3, 67-68 (2003).
11. Shinabarger D. Mechanism of action of the oxazolidinone antibacterial agents. Exp. Opin. Investig. Drugs 8, 1195-1202 (1999).
12. Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358, 207-208 (2001).
13. Labischinski H, Ehlert K, Wieland B. Novel antistaphylococcal targets and compounds. Exp. Opin. Investig. Drugs 7, 1245-1256 (1998).
14. Woodford N. Novel agents for the treatment of resistant Gram-positive infections. Exp. Opin. Investig. Drugs 12, 117-137 (2003).
15. Neu HC. The crisis in antibiotic resistance. Science 257, 1064-1073 (1992).
16. Chambers HF. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin. Microbiol. Rev. 10, 781-791 (1997).
17. Russell AD, Chopra I. Understanding Antibacterial Action and Resistance (2nd Edition). Ellis Horwood, Chichester, UK, (1996).
18. Livermore DM. Antibiotic resistance in staphylococci. Int. J. Antimicrob. Agents 16, S3-S10 (2000).
19. Schaaff F, Reipert A, Bierbaum G. An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 46, 3540-3548 (2002).
20. O'Neill AJ, Chopra I. Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low. J. Antimicrob. Chemother. 50, 161-169 (2002).
21. O'Neill AJ, Chopra I. Lack of evidence for involvement of hypermutability in emergence of vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 1484-1485 (2003).
22. Miller K, O'Neill AJ, Chopra I. Response of Escherichia coli hypermutators to selection pressure with antimicrobial agents from different classes. J. Antimicrob. Chemother. 49, 925-934 (2002).
23. Gholizadeh Y, Courvalin P. Acquired and intrinsic glycopeptide resistance in enterococci. Int. J. Antimicrob. Agents 16, S11-S17 (2000).
24. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett. 72, 195-198 (1992).
25. Projan SJ, Youngman PJ. Antimicrobials: new solutions badly needed. Curr. Opin. Microbiol 5, 463-465 (2002).
26. Pillai SK, Sakoulas G, Wennersten C et al. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J. Inf. Dis. 186, 1603-1607 (2002).
27. Chopra I. Protein synthesis as a target for antibacterial drugs: current status and future opportunities. Exp. Opin. Investig. Drugs 7, 1237-1244 (1998).
28. Bayliss CD, Moxon RE. Hypermutation and bacterial adaptation. ASM News 68, 549-555 (2002).
29. Lomovskaya O, Watkins W. Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. J. Mol. Microbiol. Biotechnol. 3, 225-236 (2001).
30. Renau TE, Lemoine RC. Efflux pump inhibitors to address bacterial and fungal resistance. Drugs Future 26, 1171-1178 (2001).
31. Kaatz GW, Moudgal VV, Seo SM et al. Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 719-726 (2003).
32. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65, 232-260 (2001).
33. Zahner H, Fiedler H-P. The need for new antibiotics: possible ways forward. In: Past Perspectives and Future Trends. Hunter PA, Darby GK, Russell NJ (Eds), Cambridge University Press, Cambridge, UK, 67-84 (1996).
34. Arbiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. J. Am. Acad. Dermatol. 32, 241-247 (1995).
35. Chopra I, Brennan P. Molecular action of antimycobacterial agents. Tuber. Lung Dis. 78, 89-98 (1998).
36. Van Rensburg CEJ, Joone GK, O'Sullivan JF et al. Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids. Antimicrob. Agents Chemother. 36, 2729-2735 (1992).
37. De Bruyn EE, Steel HC, Van Rensburg CEJ et al. The riminophenazines, clofazimine and B669, inhibit potassium transport in Gram-positive bacteria by a lysophospholipid-dependent mechanism. J. Antimicrob. Chemother. 38, 349-362 (1996).
38. Oliva B, Commanducci A, Chopra I. Antibacterial spectra of drugs used for chemotherapy of mycobacterial infections. Tuber. Lung Dis. 79, 107-109 (1998).
39. 2 activity. J. Antimicrob. Chemother. 44, 209-216 (1999).
40. Chopra I. Research and development of antibacterial agents. Curr. Opin. Microbiol. 1, 495-501 (1998).
41. Payne DJ, Wallis NG, Gentry DR et al. The impact of genomics on novel antibacterial targets. Current Opin. Drug Disc. Develop. 3, 177-190 (2000).
42. McDevitt D, Rosenberg M. Exploiting genomics to discover new antibiotics. Trends Microbiol. 9, 611-617 (2001).
43. McDevitt D, Payne DJ, Holmes DJ, Rosenberg M. Novel targets for the future development of antibacterial agents. J. Appl. Microbiol. Symp. Suppl. 92, 28S-34S (2002)
44. Hackbarth CJ, Chen DZ, Lewis JG et al. N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob. Agents Chemother. 46, 2752-2746 (2002).
45. Horton JR, Bostock JM, Chopra I et al. Macrocyclic inhibitors of the bacterial cell wall biosynthesis enzyme MurD. Bioorg. Med. Chem. Lett. 13, 1557-1560 (2003).
46. Cramer P. Multisubunit RNA polymerases. Curr. Opin. Str. Biol. 12, 89-97 (2002).